← Leaderboards
Thomas Rivenburg
Soligenix, Inc.
$7,041,180
Attributed
$7,041,180
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2013–16$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
Funding mix
By agency
NIH$7,041,180 · 1
By mechanism
N01$7,041,180 · 1
Top collaborators
No co-investigators on record.
Most similar at Soligenix, Inc.
Same institution · by research overlap
- Kevin James Horgan$1,337,803
- Christopher Joseph Schaber$954,020
- Robert Brey$21,224,085
- Richard Conrad Straube$3,189,817
- Oreola Donini$1,916,410
Others in their field
Top investigators on “Syndrome”
- David Heimbrook · Leidos Biomedical Research, Inc.$365,165,418
- George R Seage · Abt Associates, Inc.$241,364,559
- Barbara Driver · Westat, Inc.$177,853,041
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$174,377,607
- Michelle Vargas · Ppd Development Lp$163,846,102
- Judith S. Currier · University Of California Los Angeles$149,333,820
Research focus
SyndromeAdvanced DevelopmentAnimal ModelAnimal Model DevelopmentAwardBeclomethasoneContractsDoseDrug KineticsEfficacy TestingGastrointestinalMedicalRadiation SyndromesAcuteRadiation Toxicity
Grant awards (4)
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$575,242
N01 · FY2016 · AI · contact PI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,168,425
N01 · FY2015 · AI · contact PI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,165,100
N01 · FY2014 · AI · contact PI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,132,413
N01 · FY2013 · AI · contact PI